.Attributes Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of clients with HER2+ innovative breast cancer cells and also energetic or steady mind metastases revealed consistent intracranial activity and systemic effectiveness of T-DXd.